Targeting signal pathways active in cancer stem cells to overcome drug resistance

Chinese Journal of Lung Cancer

Volumn 12, Issue 1, 2009, Pages 3-7

  She, Miaorong ^a   Chen, Xilin ^b  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO N [4 [5 (2 PHENANTHRENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]PHENYL]ACETAMIDE; 2 MORPHOLINO 8 PHENYLCHROMONE; 3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BAG 956; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CD135 ANTIGEN; CELECOXIB; CYCLOPAMINE; CYTARABINE; DASATINIB; DAUNORUBICIN; EVEROLIMUS; IDARUBICIN; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MANUMYCIN; MITOXANTRONE; NUCLEOSIDE ANALOG; PARTHENOLIDE; PERIFOSINE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN KINASE B; RAPAMYCIN; RAS PROTEIN; SONIC HEDGEHOG PROTEIN; TAMOXIFEN; TEMOZOLOMIDE; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CANCER STEM CELL; CELL GROWTH; CELL SURVIVAL; DRUG EFFECT; DRUG RESISTANCE; HUMAN; MOLECULAR BIOLOGY; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

EID: 60149084188     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: 10.3779/j.issn.1009-3419.2009.01.001     Document Type: Review

References (48)

1. Peacock CD, Watkins DN. Cancer stem cells and the ontogeny of lung cancer. J Clin Oncol, 2008, 26(17): 2883-2889.
2. Shafee N, Smith CR, Wei S, et al. Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res, 2008, 68(9): 3243-3250.
3. + HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene, 2008, 27(12): 1749-1758.
4. Francipane MG, Alea MP, Lombardo Y, et al. Crucial role of interleukin-4 in the survival of colon cancer stem cells. Cancer Res, 2008, 68(11): 4022-4025.
5. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med, 1997, 3(7): 730-737.
6. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature, 2004, 432(7015): 396-401.
7. Waterworth A. Introducing the concept of breast cancer stem cells. Breast Cancer Res, 2004, 6(1): 53-54.
8. Collins AT, Berry PA, Hyde C, et al. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res, 2005, 65(23): 10946-10951.
9. O'Brien CA, Pollett A, Gallinger S, et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature, 2007, 445(7123): 106-110.
10. Chiba T, Kita K, Zheng YW, et al. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology, 2006, 44(1): 240-251.
11. Prince ME, Ailles LE. Cancer stem cells in head and neck squamous cell cancer. J Clin Oncol, 2008, 26(17): 2871-2875.
12. Todaro M, Perez Alea M, Scopelliti A, et al. IL-4-mediated drug resistance in colon cancer stem cells. Cell Cycle, 2008, 7(3): 309-313.
13. Lu C, Shervington A. Chemoresistance in gliomas. Mol Cell Biochem, 2008, 312(1-2): 71-80.
14. Eramo A, Ricci-Vitiani L, Zeuner A, et al. Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ, 2006, 13(7): 1238-1241.
15. Ravandi F, Estrov Z. Eradication of leukemia stem cells as a new goal of therapy in leukemia. Clin Cancer Res, 2006, 12(2): 340-344.
16. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radio-resistance by preferential activation of the DNA damage response. Nature, 2006, 444(7120): 756-760.
17. Zobalova R, McDermott L, Stantic M, et al. CD133-positive cells are resistant to TRAIL due to up-regulation of FLIP. Biochem Biophys Res Commun, 2008, 373(4): 567-571.
18. Wei C, Guo-min W, Yu-jun L. Apoptosis resistance can be used in screening the markers of cancer stem cells. Med Hypotheses, 2006, 67(6): 1381-1383.
19. Liu S, Dontu G, Mantle ID, et al. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res, 2006, 66(12): 6063-6071.
20. Clement V, Sanchez P, de Tribolet N, et al. HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr Biol, 2007, 17(2): 165-172.
21. Kubo M, Kuroki S, Tanaka M. New therapeutic target of breast cancer. Nippon Rinsho, 2007, 65(Suppl 6): 142-147.
22. Tung DC, Chao KS. Targeting hedgehog in cancer stem cells: how a paradigm shift can improve treatment response. Future Oncol, 2007, 3(5): 569-574.
23. Vestergaard J, Lind-Thomsen A, Pedersen MW, et al. GLI1 is involved in cell cycle regulation and proliferation of NT2 embryonal carcinoma stem cells. DNA Cell Biol, 2008, 27(5): 251-256.
24. Lou H, Dean M. Targeted therapy for cancer stem cells: the patched pathway and ABC transporters. Oncogene, 2007, 26(9): 1357-1360.
25. Styczynski J, Drewa T. Leukemic stem cells: from metabolic pathways and signaling to a new concept of drug resistance targeting. Acta Biochim Pol, 2007, 54(4): 717-726.
26. Levis M, Murphy KM, Pham R, et al. Internal tandem duplications of the FLT3 gene are present in leukemia stem cells. Blood, 2005, 106(2): 673-680.
27. Mony U, Jawad M, Seedhouse C, et al. Resistance to FLT3 inhibition in an in vitro model of primary AML cells with a stem cell phenotype in a defined micro environment. Leukemia, 2008, 22(7): 1395-1401.
28. - precursors predicts poor outcome in acute myeloid leukemia. Blood, 2006, 108(8): 2704-2769.
29. Tazzari PL, Cappellini A, Ricci F, et al. Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/ Akt signal transduction network in human acute myelogenous leukemia blasts. Leukemia, 2007, 21(3): 427-438.
30. Hambardzumyan D, Becher OJ, Rosenblum MK, et al. PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev, 2008, 22(4): 436-448.
31. Yilmaz OH, Morrison SJ. The PI-3kinase pathway in hematopoietic stem cells and leukemia-initiating cells: a mechanistic difference between normal and cancer stem cells. Blood Cells Mol Dis, 2008, 41(1): 73-76.
32. Yilmaz OH, Valdez R, Theisen BK, et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature, 2006, 441(7092): 475-482.
33. Yanagi S, Kishimoto H, Kawahara K, et al. Pten controls lung morphogenesis, bronchioalveolar stem cells, and onset of lung adenocarcinomas in mice. J Clin Invest, 2007, 117(10): 2929-2940.
34. Shoman N, Klassen S, McFadden A, et al. Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen. Mod Pathol, 2005, 18(2): 250-259.
35. Guzman ML, Neering SJ, Upchurch D, et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood, 2001, 98(8): 2301-2307.
36. Guzman ML, Swiderski CF, Howard DS, et al. Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci USA, 2002, 99(25): 16220-16225.
37. Kumar SK, Roy I, Anchoori RK, et al. Targeted inhibition of hedgehog signaling by cyclopamine prodrugs for advanced prostate cancer. Bioorg Med Chem, 2008, 16(6): 2764-2768.
38. Kim Y, Yoon JW, Xiao X, et al. Selective down-regulation of glioma-associated oncogene 2 inhibits the proliferation of hepatocellular carcinoma cells. Cancer Res, 2007, 67(8): 3583-3593.
39. Peacock CD, Wang Q, Gesell GS, et al. Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc Natl Acad Sci USA, 2007, 104(10): 4048-4053.
40. Bar EE, Chaudhry A, Lin A, et al. Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells, 2007, 25(10): 2524-2533.
41. Copland M, Pellicano F, Richmond L, et al. BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Blood, 2008, 111(5): 2843-2853.
42. Tabe Y, Jin L, Tsutsumi-Ishii Y, et al. Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells. Cancer Res, 2007, 67(2): 684-694.
43. Zhou J, Wulfkuhle J, Zhang H, et al. Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci USA, 2007, 104(41): 16158-16163.
44. Weisberg E, Banerji L, Wright RD, et al. Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL-and mutant FLT3-expressing cells. Blood, 2008, 111(7): 3723-3734.
45. Guzman ML, Rossi RM, Kamischky L, et al. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood, 2005, 105(11): 4163-4169.
46. Guzman ML, Rossi RM, Neelakantan S, et al. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood, 2007, 110(13): 4427-4435.
47. Servida F, Soligo D, Delia D, et al. Sensitivity of human multiple myelomas and myeloid leukemias to the proteasome inhibitor I. Leukemia, 2005, 19(12): 2324-2331.
48. Guzman ML, Li X, Corbett CA, et al. Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8). Blood, 2007, 110(13): 4436-4444.